Macrophages in renal development, injury, and repair

Seminars in Nephrology

Volumn 30, Issue 3, 2010, Pages 255-267

  Williams, Timothy M ^a   Little, Melissa H ^b   Ricardo, Sharon D ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Alternative activation; Chemokines; Classic activation; CSF 1; Innate immunity; Kidney development; Macrophage

Indexed keywords

CYTOKINE;

APOPTOSIS; ARTICLE; CELL HETEROGENEITY; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; GENETIC MANIPULATION; GLOMERULUS; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; KIDNEY CANCER; KIDNEY DEVELOPMENT; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MEDIATOR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TISSUE REPAIR; TURNOVER TIME;

ACUTE KIDNEY INJURY; ANIMALS; CHRONIC DISEASE; HUMANS; KIDNEY; KIDNEY DISEASES; MACROPHAGE ACTIVATION; MACROPHAGES; REGENERATION;

EID: 77953900264     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.03.011     Document Type: Article

References (98)

1. van Furth R., Cohn Z.A., Hirsch J.G., Humphrey J.H., Spector W.G., Langevoort H.L. Mononuclear phagocytic system: new classification of macrophages, monocytes and of their cell line. Bull World Health Organ 1972, 47:651-658.
2. Takahashi K., Naito M. Development, differentiation, and proliferation of macrophages in the rat yolk sac. Tissue Cell 1993, 25:351-362.
3. Hume D.A. The mononuclear phagocyte system. Curr Opin Immunol 2006, 18:49-53.
4. Lichanska A.M., Browne C.M., Henkel G.W., Murphy K.M., Ostrowski M.C., McKercher S.R., et al. Differentiation of the mononuclear phagocyte system during mouse embryogenesis: the role of transcription factor PU.1. Blood 1999, 94:127-138.
5. Ovchinnikov D.A. Macrophages in the embryo and beyond: much more than just giant phagocytes. Genesis 2008, 46:447-462.
6. Takeya M., Takahashi K. Ontogenic development of macrophage subpopulations and Ia-positive dendritic cells in fetal and neonatal rat spleen. J Leukoc Biol 1992, 52:516-523.
7. Izumi S., Takeya M., Takagi K., Takahashi K. Ontogenetic development of synovial A cells in fetal and neonatal rat knee joints. Cell Tissue Res 1990, 262:1-8.
8. Henson P.M., Hume D.A. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol 2006, 27:244-250.
9. Cohen P.E., Chisholm O., Arceci R.J., Stanley E.R., Pollard J.W. Absence of colony-stimulating factor-1 in osteopetrotic (csfmop/csfmop) mice results in male fertility defects. Biol Reprod 1996, 55:310-317.
10. Dai X.-M., Ryan G.R., Hapel A.J., Dominguez M.G., Russell R.G., Kapp S., et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002, 99:111-120.
11. Michaelson M.D., Bieri P.L., Mehler M.F., Xu H., Arezzo J.C., Pollard J.W., et al. CSF-1 deficiency in mice results in abnormal brain development. Development 1996, 122:2661-2672.
12. Van Nguyen A., Pollard J.W. Colony stimulating factor-1 is required to recruit macrophages into the mammary gland to facilitate mammary ductal outgrowth. Dev Biol 2002, 247:11-25.
13. Banaei-Bouchareb L., Gouon-Evans V., Samara-Boustani D., Castellotti M.C., Czernichow P., Pollard J.W., et al. Insulin cell mass is altered in Csf1op/Csf1op macrophage-deficient mice. J Leukoc Biol 2004, 76:359-367.
14. Shepard J.L., Zon L.I. Developmental derivation of embryonic and adult macrophages. Curr Opin Hematol 2000, 7:3-8.
15. Lichanska A.M., Hume D.A. Origins and functions of phagocytes in the embryo. Exp Hematol 2000, 28:601-611.
16. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
17. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483.
18. Cassol E., Cassetta L., Rizzi C., Alfano M., Poli G. M1 and M2a Polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol 2009, 182:6237-6246.
19. Verreck F.A.W., de Boer T., Langenberg D.M.L., Hoeve M.A., Kramer M., Vaisberg E., et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A 2004, 101:4560-4565.
20. MacMicking J., Xie Q.-W., Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997, 15:323-350.
21. Nathan C., Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A 2000, 97:8841-8848.
22. Kito T., Kuroda E., Yokota A., Yamashita U. Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18 stimulated macrophages mediated by interferon-γ regulated by nitric oxide. J Neurosurg 2003, 98:385-392.
23. Ricardo S.D., van Goor H., Eddy A.A. Macrophage diversity in renal injury and repair. J Clin Invest 2008, 118:3522-3530.
24. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
25. Watanabe K., Jose P.J., Rankin S.M. Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages. J Immunol 2002, 168:1911-1918.
26. Gratchev A., Guillot P., Hakiy N., Politz O., Orfanos C., Schledzewski K., et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol 2001, 53:386-392.
27. Gibson M.A., Kumaratilake J.S., Cleary E.G. Immunohistochemical and ultrastructural localization of MP78/70 (big-h3) in extracellular matrix of developing and mature bovine tissues. J Histochem Cytochem 1997, 45:1683-1696.
28. Tsuboi R., Shi C.-M., Sato C., Cox G.N., Ogawa H. Co-administration of insulin-like growth factor (IGF)-I and IGF-binding protein-1 stimulates wound healing in animal models. J Investig Dermatol 1995, 104:199-203.
29. Kratz G., Lake M., Gidlund M. Insulin like growth factor-1 and -2 and their role in the re-epithelialisation of wounds; interactions with insulin like growth factor binding protein type 1. Scand J Plast Reconstr Surg Hand Surg 1994, 28:107-112.
30. Elsner J., Escher S.E., Forssmann U. Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy 2004, 59:1243-1258.
31. Gerber J.S., Mosser D.M. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol 2001, 166:6861-6868.
32. Anderson C.F., Mosser D.M. Cutting edge: biasing immune responses by directing antigen to macrophage Fc{gamma} receptors. J Immunol 2002, 168:3697-3701.
33. Anderson C.F., Mosser D.M. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002, 72:101-106.
34. Sozzani S., Ghezzi S., Iannolo G., Luini W., Borsatti A., Polentarutti N., et al. Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med 1998, 187:439-444.
35. Bleharski J.R., Niazi K.R., Sieling P.A., Cheng G., Modlin R.L. Signaling lymphocytic activation molecule is expressed on CD40 ligand-activated dendritic cells and directly augments production of inflammatory cytokines. J Immunol 2001, 167:3174-3181.
36. Punnonen J., Cocks B.G., Carballido J.M., Bennett B., Peterson D., Aversa G., et al. Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes. J Exp Med 1997, 185:993-1004.
37. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
38. Rae F., Woods K., Sasmono T., Campanale N., Taylor D., Ovchinnikov D.A., et al. Characterisation and trophic functions of murine embryonic macrophages based upon the use of a Csf1r-EGFP transgene reporter. Dev Biol 2007, 308:232-246.
39. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
40. Greaves D.R., Gordon S. Macrophage-specific gene expression: current paradigms and future challenges. Int J Hematol 2002, 76:6-15.
41. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155-1166.
42. Lamagna C., Aurrand-Lions M., Imhof B.A. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006, 80:705-713.
43. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
44. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
45. Tsuda Y., Takahashi H., Kobayashi M., Hanafusa T., Herndon D.N., Suzuki F. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 2004, 21:215-226.
46. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964.
47. Kelly J., Ali Khan A., Yin J., Ferguson T.A., Apte R.S. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest 2007, 117:3421-3426.
48. Luo Y., Zhou H., Krueger J., Kaplan C., Lee S.H., Dolman C., et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006, 116:2132-2141.
49. Gouon-Evans V., Lin E., Pollard J. Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res 2002, 4:155-164.
50. Roth P., Dominguez M.G., Stanley E.R. The effects of colony-stimulating factor-1 on the distribution of mononuclear phagocytes in the developing osteopetrotic mouse. Blood 1998, 91:3773-3783.
51. Humphreys B.D., Bonventre J.V. The contribution of adult stem cells to renal repair. Nephrol Ther 2007, 3:3-10.
52. Shikata K., Makino H. Role of macrophages in the pathogenesis of diabetic nephropathy. Contrib Nephrol 2001, 134:46-54.
53. Huang X.R., Tipping P.G., Apostolopoulos J., Oettinger C., D'Souza M., Milton G., et al. Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats. Clin Exp Immunol 1997, 109:134-142.
54. Tesch G.H., Maifert S., Schwarting A., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999, 190:1813-1824.
55. Lange-Sperandio B., Cachat F., Thornhill B.A., Chevalier R.L. Selectins mediate macrophage infiltration in obstructive nephropathy in newborn mice. Kidney Int 2002, 61:516-524.
56. Khan S., Cleveland R.P., Koch C.J., Schelling J.R. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest 1999, 79:1089-1099.
57. Kang D.-H., Joly A.H., Oh S.-W., Hugo C., Kerjaschki D., Gordon K.L., et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001, 12:1434-1447.
58. Mori T., Bartocci A., Satriano J., Zuckerman A., Stanley R., Santiago A., et al. Mouse mesangial cells produce colony-stimulating factor-1 (CSF-1) and express the CSF-1 receptor. J Immunol 1990, 144:4697-4702.
59. Gerharz C.-D., Reinecke P., Schneider E.M., Schmitz M., Gabbert H.E. Secretion of GM-CSF and M-CSF by human renal cell carcinomas of different histologic types. Urology 2001, 58:821-827.
60. Isbel N.M., Hill P.A., Foti R., Mu W., Hurst L.A., Stambe C., et al. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int 2001, 60:614-625.
61. Isbel N.M., Nikolic-Paterson D.J., Hill P.A., Dowling J., Atkins R.C. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol Dial Transplant 2001, 16:1638-1647.
62. Lenda D.M., Kikawada E., Stanley E.R., Kelley V.R. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J Immunol 2003, 170:3254-3262.
63. Le Meur Y., Leprivey-Lorgeot V., Mons S., Jose M., Dantal J., Lemauff B., et al. Serum levels of macrophage-colony stimulating factor (M-CSF): a marker of kidney allograft rejection. Nephrol Dial Transplant 2004, 19:1862-1865.
64. Jose M.D., Le Meur Y., Atkins R.C., Chadban S.J. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am J Transplant 2003, 3:294-300.
65. Menke J. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest 2009, 119:2330-2342.
66. Nguyen D., Ping F., Mu W., Hill P., Atkins R.C., Chadban S.J. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology 2006, 11:226-231.
67. Lim A., Ma F., Nikolic-Paterson D., Thomas M., Hurst L., Tesch G. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009, 52:1669-1679.
68. Naito T., Yokoyama H., Moore K.J., Dranoff G., Mulligan R.C., Kelley V.R. Macrophage growth factors introduced into the kidney initiate renal injury. Mol Med 1996, 2:297-312.
69. Pull S.L., Doherty J.M., Mills J.C., Gordon J.I., Stappenbeck T.S. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A 2005, 102:99-104.
70. Rice E.K., Nikolic-Paterson D.J., David J.R., Bucala R., Metz C.N., Atkins R.C., et al. Macrophage accumulation and renal fibrosis are independent of macrophage migration inhibitory factor in mouse obstructive nephropathy. Nephrology 2004, 9:278-287.
71. Ophascharoensuk V., Giachelli C.M., Gordon K., Hughes J., Pichler R., Brown P., et al. Obstructive uropathy in the mouse: Role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999, 56:571-580.
72. Nony P.A., Schnellmann R.G. Mechanisms of renal cell repair and regeneration after acute renal failure. J Pharmacol Exp Ther 2003, 304:905-912.
73. Jo S.-K., Sung S.-A., Cho W.-Y., Go K.-J., Kim H.-K. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant 2006, 21:1231-1239.
74. Otero K., Turnbull I.R., Poliani P.L., Vermi W., Cerutti E., Aoshi T., et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and [beta]-catenin. Nat Immunol 2009, 10:734-743.
75. Aharinejad S., Marks S.C., Bck P., Mason-Savas A., MacKay C.A., Larson E.K., et al. CSF-1 treatment promotes angiogenesis in the metaphysis of osteopetrotic (toothless, tl) rats. Bone 1995, 16:315-324.
76. Eubank T.D., Galloway M., Montague C.M., Waldman W.J., Marsh C.B. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 2003, 171:2637-2643.
77. Johnson C., Sung H.-J., Lessner S.M., Fini M.E., Galis Z.S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 2004, 94:262-268.
78. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740.
79. Aharinejad S., Paulus P., Sioud M., Hofmann M., Zins K., Schafer R., et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004, 64:5378-5384.
80. Paulus P., Stanley E.R., Schafer R., Abraham D., Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006, 66:4349-4356.
81. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjallman A.H.M., Ballmer-Hofer K., Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006, 95:272-281.
82. Kubota Y., Takubo K., Shimizu T., Ohno H., Kishi K., Shibuya M., et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009, 206:1089-1102.
83. Murphy G., Nguyen Q., Cockett M.I., Atkinson S.J., Allan J.A., Knight C.G., et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 1994, 269:6632-6636.
84. Ashworth J.L., Murphy G., Rock M.J., Sherratt M.J., Shapiro S.D., Shuttleworth C.A., et al. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J 1999, 340:171-181.
85. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
86. Somerville R., Oblander S., Apte S. Matrix metalloproteinases: old dogs with new tricks. Genome Biol 2003, 4:216.
87. Allen A.R., McHale J., Smith J., Cook H.T., Karkar A., Haskard D.O., et al. Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury. J Immunol 1999, 162:5519-5527.
88. Erwig L.-P., Kluth D.C., Rees A.J. Macrophages in renal inflammation. Curr Opin Nephrol Hypertens 2001, 10:341-347.
89. Rao V.H., Meehan D.T., Delimont D., Nakajima M., Wada T., Gratton M.A., et al. Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome. Am J Pathol 2006, 169:32-46.
90. Yokoo T., Ohashi T., Utsunomiya Y., Kojima H., Imasawa T., Kogure T., et al. Prophylaxis of antibody-induced acute glomerulonephritis with genetically modified bone marrow-derived vehicle cells. Hum Gene Ther 1999, 10:2673-2678.
91. Yang J., Reutzel-Selke A., Steier C., Jurisch A., Tullius S.G., Sawitzki B., et al. Targeting of macrophage activity by adenovirus-mediated intragraft overexpression of TNFRp55-Ig, IL-12p40, and vIL-10 ameliorates adenovirus-mediated chronic graft injury, whereas stimulation of macrophages by overexpression of IFN-gamma accelerates chronic graft injury in a rat renal allograft model. J Am Soc Nephrol 2003, 14:214-225.
92. Nishida M., Okumura Y., Fujimoto S., Shiraishi I., Itoi T., Hamaoka K. Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem Biophys Res Commun 2005, 332:11-16.
93. Munger K.A., Montero A., Fukunaga M., Uda S., Yura T., Imai E., et al. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci U S A 1999, 96:13375-13380.
94. Kluth D.C., Ainslie C.V., Pearce W.P., Finlay S., Clarke D., Anegon I., et al. Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. J Immunol 2001, 166:4728-4736.
95. Wilson H.M., Chettibi S., Jobin C., Walbaum D., Rees A.J., Kluth D.C. Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory phenotype that attenuates glomerular inflammation in vivo. Am J Pathol 2005, 167:27-37.
96. Wilson H.M., Chettibi S., Jobin C., Walbaum D., Rees A.J., Kluth D.C. Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory phenotype that attenuates glomerular inflammation in vivo. Am J Pathol 2005, 167:27-37.
97. Yokoo T., Ohashi T., Utsunomiya Y., Shen J.S., Hisada Y., Eto Y., et al. Genetically modified bone marrow continuously supplies anti-inflammatory cells and suppresses renal injury in mouse Goodpasture syndrome. Blood 2001, 98:57-64.
98. Wang Y., Wang Y.P., Zheng G., Lee V.W., Ouyang L., Chang D.H., et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007, 72:290-299.